Celcuity

Celcuity EBIT per Employee

The EBIT per Employee of Celcuity (CELC) as of Sep 27, 2026 is -1.11 M USD. In the previous year, EBIT per Employee was -730,754.52 USD — a change of 52.02% (lower).

EBIT per Employee

-1.11 MUSD

YoY

52.02%

Last updated:

EBIT per Employee of Celcuity is 2026 -1.11 M USD. EBIT per Employee of Celcuity was 2025 -730,754.52 USD. It decreases by 52.02% lower compared to the previous year.

The Celcuity EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2018
-51,177.66 USD
Jan 1, 2019
-50,356.78 USD
Jan 1, 2020
-61,652.67 USD
Jan 1, 2021
-182,943.08 USD
Jan 1, 2022
-254,136.06 USD
Jan 1, 2023
-427,292.45 USD
Jan 1, 2024
-730,754.52 USD
Jan 1, 2025
-1.11 M USD
The Celcuity EBIT per Employee history
YEAREBIT per EmployeeYoY
-1.11 MUSD+52.02%
-730,754.52USD+71.02%
-427,292.45USD+68.14%
-254,136.06USD+38.92%
-182,943.08USD+196.73%
-61,652.67USD+22.43%
-50,356.78USD-1.60%
-51,177.66USD+33.25%
-38,406.10USD+78.85%
-21,473.72USD+47.16%
-14,592.32USD—
Access this data via the Eulerpool API

Celcuity Stock analysis

What does Celcuity do? Celcuity Inc is a biotechnology company founded by Brian Sullivan in 2012. The company is headquartered in Minneapolis, USA. The business model of Celcuity is based on researching and developing new diagnostic and treatment methods for various types of cancer. The company utilizes a proprietary technology platform called CELx, which enables the analysis of cancer cell signaling pathways and the development of individualized treatment strategies. Celcuity specializes in the development of diagnostics and personalized therapies based on individual cancer cell signaling pathways. The company operates in two divisions: 1. Diagnostics division: Celcuity's diagnostics division focuses on identifying new cancer markers and biomarkers for early detection of cancer and the development of individualized treatment strategies. 2. Therapy division: Celcuity's therapy division specializes in the development of personalized therapies based on individual cancer cell signaling pathways. Celcuity currently offers two products based on the CELx technology platform: 1. CELx HUB: CELx HUB is a cloud-based software that allows doctors and researchers to analyze cancer samples and develop individualized treatment strategies. 2. CELx TIL: CELx TIL is a diagnostic tool that measures the presence of tumor cells in the immune system of cancer patients. In summary, Celcuity Inc is a leader in the field of personalized cancer therapy based on individual cancer cell signaling pathways. The company has found a niche in this growing market and has a unique technology platform that allows it to serve its customers effectively. With its products and services, Celcuity is helping to revolutionize cancer treatment and improve the quality of life for cancer patients worldwide. Celcuity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celcuity stock

EBIT per Employee of Celcuity is -1.11 M USD in 2026.

EBIT per Employee of Celcuity changed from -730,754.52 USD to -1.11 M USD, representing a 52.02% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Celcuity since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Celcuity historically and in real time.

Access this data via the Eulerpool API

Workforce — Celcuity

All Key Metrics — Celcuity